Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics
- Author
- Peter Brouckaert (UGent) , N TAKAHASHI, ST VAN TIEL, Jeroen Hostens, AMM EGGERMONT, ALB SEYNHAEVE, Walter Fiers and TLM TEN HAGEN
- Organization
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 341.99 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-210480
- MLA
- Brouckaert, Peter, et al. “Tumor Necrosis Factor-Alpha Augmented Tumor Response in B16BL6 Melanoma-Bearing Mice Treated with Stealth Liposomal Doxorubicin (DOXIL (R)) Correlates with Altered DOXIL (R) Pharmacokinetics.” INTERNATIONAL JOURNAL OF CANCER, vol. 109, no. 3, 2004, pp. 442–48, doi:10.1002/ijc.11703.
- APA
- Brouckaert, P., TAKAHASHI, N., VAN TIEL, S., Hostens, J., EGGERMONT, A., SEYNHAEVE, A., … TEN HAGEN, T. (2004). Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics. INTERNATIONAL JOURNAL OF CANCER, 109(3), 442–448. https://doi.org/10.1002/ijc.11703
- Chicago author-date
- Brouckaert, Peter, N TAKAHASHI, ST VAN TIEL, Jeroen Hostens, AMM EGGERMONT, ALB SEYNHAEVE, Walter Fiers, and TLM TEN HAGEN. 2004. “Tumor Necrosis Factor-Alpha Augmented Tumor Response in B16BL6 Melanoma-Bearing Mice Treated with Stealth Liposomal Doxorubicin (DOXIL (R)) Correlates with Altered DOXIL (R) Pharmacokinetics.” INTERNATIONAL JOURNAL OF CANCER 109 (3): 442–48. https://doi.org/10.1002/ijc.11703.
- Chicago author-date (all authors)
- Brouckaert, Peter, N TAKAHASHI, ST VAN TIEL, Jeroen Hostens, AMM EGGERMONT, ALB SEYNHAEVE, Walter Fiers, and TLM TEN HAGEN. 2004. “Tumor Necrosis Factor-Alpha Augmented Tumor Response in B16BL6 Melanoma-Bearing Mice Treated with Stealth Liposomal Doxorubicin (DOXIL (R)) Correlates with Altered DOXIL (R) Pharmacokinetics.” INTERNATIONAL JOURNAL OF CANCER 109 (3): 442–448. doi:10.1002/ijc.11703.
- Vancouver
- 1.Brouckaert P, TAKAHASHI N, VAN TIEL S, Hostens J, EGGERMONT A, SEYNHAEVE A, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics. INTERNATIONAL JOURNAL OF CANCER. 2004;109(3):442–8.
- IEEE
- [1]P. Brouckaert et al., “Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics,” INTERNATIONAL JOURNAL OF CANCER, vol. 109, no. 3, pp. 442–448, 2004.
@article{210480, author = {{Brouckaert, Peter and TAKAHASHI, N and VAN TIEL, ST and Hostens, Jeroen and EGGERMONT, AMM and SEYNHAEVE, ALB and Fiers, Walter and TEN HAGEN, TLM}}, issn = {{0020-7136}}, journal = {{INTERNATIONAL JOURNAL OF CANCER}}, language = {{eng}}, number = {{3}}, pages = {{442--448}}, title = {{Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL (R)) correlates with altered DOXIL (R) pharmacokinetics}}, url = {{http://doi.org/10.1002/ijc.11703}}, volume = {{109}}, year = {{2004}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: